Qocket No. <u>033393/055194</u>

**PATENT** 

SEP 1 9 2005 8

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

application of:

LIERBERMAN, Judy; SHANKAR, Premlata; NARASIMHASWAMY,

Manjunath; SONG, Erwei; LEE, Sang-Kyung; INCE, Nedim

Application No.:

10/533,622

Group No.:

Not yet assigned

Filed:

April 29, 2005

Examiner:

Not yet assigned

For:

METHODS FOR TREATING AND PREVENTING APOPTOSIS-

RELATED DISEASES USING RNA INTERFERING AGENTS

MAIL STOP AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a)

I hereby certify that the attached correspondence comprising:

- 1. Certificate of Mailing (1 page);
- 2. Transmittal Form (1 page);
- 3. Information Disclosure Statement with Form 1449 (3 pages);
- 4. COPY References C1-C11;
- 5. COPY Limited Recognition Statement (1 pg); and
- 6. Return Receipt Postcard.

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Date:

Signature

CATHERINE KEARNS

(type or print name of person certifying)

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, h		ection of information unless it displays a valid OMB control number.
	Application Number	10/533,622
TRANSMITTAL	Filing Date	April 29, 2005
FOR <b>M</b>	First Named Inventor	Judy Lieberman
2	Art Unit	Not yet assigned
(As he could for all assumption of the initial File	Examiner Name	Not yet assigned
(to be used for all correspondence after initial fili	Attorney Docket Number	033393/055194
Total Number of Pages in This Submission		033393/033194
	ENCLOSURES (Check all	
Fee Transmittal Form	Drawing(s)	After Allowance Communication to TC  Appeal Communication to Board
Fee Attached	Licensing-related Papers	of Appeals and Interferences
Amendment/Reply	Petition Petition to Convert to a	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Provisional Application	Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence A	ddress Status Letter
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please Identify below):
Express Abandonment Request	Request for Refund	Certificate of Mailing; Information Disclosure Statement with Form 1449; COPY - References
X Information Disclosure Statement	CD, Number of CD(s)	C1-C11; Limited Recognition Statement; and Return Receipt Postcard
	Landscape Table on CD	·
Certified Copy of Priority	Remarks	
	Γhe Commissioner is authorized t he NIXON PEABODY LLP Dep	to charge fee deficiencies or credit overpayments to
Incomplete Application	HE MIXON I EADOD I DEL DEL	705h 7660dh 170. 50 0050.
Reply to Missing Parts under 37 CFR 1.52 or 1.53		
SIGNAT	URE OF APPLICANT, ATTO	RNEY OR AGENT
Firm Name		
NIXON PEABODY	LLP	· ·
Signature	Dell	U
Printed name David S. Resnick/Leer	na H. Karttunen	·
Date 9 (13) 2005	F	Reg. No. 34,235/L0207
CE	RTIFICATE OF TRANSMISS	ION/MAILING
I hereby certify that this correspondence is be sufficient postage as first class mail in an enve the date shown below:	ing facsimile transmitted to the USPTi elope addressed to: Commissioner for	O or deposited with the United States Postal Service with Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Signature	Kenn	
Typed or printed name CATHERINE	EKEARNS	Date 9/13/05
This collection of information is required by 37 CFR process) an application. Confidentiality is governed	1.5. The information is required to obtain o	r retain a benefit by the public which is to file (and by the USPTO to .14. This collection is estimated to 2 hours to complete, including

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

# BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE UNITED STATES PATENT AND TRADEMARK OFFICE

# LIMITED RECOGNITION UNDER 37 CFR § 11.9(b)

Leena H. Karttunen is hereby given limited recognition under 37 CFR § 11.9(b), as an employee of the law firm of Nixon Peabody LLP, to prepare and prosecute patent applications wherein the patent applicant is a client of the law firm of Nixon Peabody LLP, and a registered practitioner, who is a member of the law firm of Nixon Peabody LLP, is the practitioner of record in the applications. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Leena H. Karttunen ceases to lawfully reside in the United States, (ii) Leena H. Karttunen's employment with the law firm of Nixon Peabody LLP, ceases or is terminated, or (iii) Leena H. Karttunen ceases to remain or reside in the United States on an H-1B visa.

This document constitutes proof of such limited recognition. The original of this document is on file in the Office of Enrollment and Discipline of the U.S. Patent and Trademark Office.

Limited Recognition No. <u>L0207</u> Expires: September 30, 2005

Harry I. Moatz

Director of Enrollment and Discipline

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LIEBERMAN, Judy; SHANKAR, Premlata; NARASIMHASWAMY, Manjunath;

SONG, Erwei; LEE, Sang-Kyung; INCE, Nedim

Application No.:

10/533,622

Group No.: To be assigned

Filed:

April 29, 2005

Examiner: To be assigned

For:

METHODS FOR TREATING AND PREVENTING APOPTOSIS-RELATED

DISEASES USING RNA INTERFERING AGENTS

#### **CERTIFICATE OF MAILING**

I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage in an envelope addressed to Mail Stop Amendment, Commissioner of Patents, Box 1450, Alexandria, VA 22313-1450

MAIL STOP AMENDMENT **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §§1.56 and 1.97, Applicants herewith submit the publications and/or patents shown on the attached form PTO-1449, for consideration by the Examiner in connection with the examination of the above-identified patent application.

#### I. REMARKS

(2)

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

X

within three (3) months of the Filing Date or before the mailing date of the First (1) Office Action on the merits; or

within three months of the mailing date of the PCT International Search Report; or

	(3)	after the period defined in (1) but before the mailing date of a Final Rejection or
		Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely
		\$180.00, is included herein; or
	(4)	after the mailing date of a Final Rejection or Notice of Allowance but before the
		payment of the Issue Fee, and the requisite Certification, petition, and petition fee are
		included herein.
	А сору	of the International Search Report is enclosed herewith.
	It is re	spectfully requested that each of the documents shown on the attached form(s)
	1449/	A/B/PTO be made of record in this application.
	Copies	s of these documents (CHECK ONE):
<u>X</u>	are end	closed herewith that have not been previously submitted; or
	have h	een cited in the parent application, and are thus not being resubmitted herein

# FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: 9//3/05

Customer No. 50828

Respectfully submitted,

David S. Resnick (Reg. 34,235) Leena H. Karttunen (L0207) NIXON PEABODY LLP 100 Summer Street

Boston, MA 02110-2131

(617) 345-6057

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

mo i aporno.	THE COURT OF THE COURT OF THE	<del></del>	Toronio are regarres to re	sepone to a concedent of informati	ion unices it displays a valid ONID control number.	
Substitute	Substitute for form 1449 PTO			Complete if Known		
i				Application Number	10/533,622	
INF	ORMATION	N DIS	CLOSURE	Filing Date	April 29, 2005	
ST/	STATEMENT BY APPLICANT			First Named Inventor	Judy Lieberman	
			,	Art Unit	To be assigned	
L	(use as many she	eets as n	ecessary)	Examiner Name	To be assigned	
Sheet	1	of	1	Attorney Docket Number	033393/55194	

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number – Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
					rigares repoeu	
				<u> </u>		

	FOREIGN PATENT DOCUMENTS					
Examiner		Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines	-
Initials*	Cite No.1	Country Code3 - Number4 - Kind Code5 (if known)	MM-DD-YYYY	Applicant Of Cited Document	Where Relevant Passages or Relevant Figures Appear	
				-		

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*					
	C1	ASHKENAZI, A. and DIXIT, V.M. Death receptors: signaling and modulation (1998) Science 281:1305-1308.			
	C2	GREEN, D.R. and EVANS, G.I. A matter of life and death (2002) Cancer Cell 1:19-30.			
	СЗ	MATTSON, M.P. Apoptosis in neurodegenerative disorders (2002) Nat. Rev. Mol. Cell. Biol. 1:120-128.			
	C4	MEIER, P., et al. Apoptosis in development (2000) Nature 407:796-801.	•		
	C5	NANSEN et al. The role of CC chemokine receptor 5 in antiviral immunity (2002) <i>Blood</i> 99:1237-1245.			
	C6	RATHMELL, J.C. and THOMPSON, C.B. Pathways of apoptosis in lymphocyte development, homeostasis, and disease (2002) <i>Cell</i> 109 (Suppl.): S97-S107.			
	C7	ROWE, P.M., Glimmers of clinical relevance for Fas (1996) Lancet, 347: 1398	i		
	C8	VAUX, D.L. and KORSMEYER, S.J. Cell death in development (1999) Cell 96:245-254.			
	C9	VERMUELEN, K., et al. Cell cycle and apoptosis (2003) Cell Prolif. 36:165-175.			
	C10	WATANABE-FUKUNAGA, R., et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen (1992) J. Immunol., 148:1274-1279			
	C11	ZÖRNIG, M., et al. Apoptosis regulators and their role in tumorigenesis (2001) <i>Biochim. Biophys. Acta</i> 1551:F1-F37.			

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.